Functional Brands closes $8 million private placement and completes Nasdaq listing
Investing.com - Baird upgraded Charles River Labs (NYSE:CRL) from Neutral to Outperform on Thursday, while raising its price target to $199.00 from $178.00. The new target represents a potential 19% upside from the current price of $167.70, which has declined 6.37% over the past week.
The research firm acknowledged that Charles River Labs did not have "a great quarter" and faces limited visibility with potential volatility ahead in the near term.
Despite these challenges, Baird expressed confidence in the company’s management of factors within its control and highlighted "tremendous cushion to protect and grow EPS until markets recover."
The upgrade comes following a recent pullback in the stock price, which Baird viewed as a favorable entry point for investors.
Baird’s analysis suggests Charles River Labs is trading at approximately 15 times conservative 2026 earnings per share estimates and less than 11 times EBITDA, indicating the firm believes long-term investment in the stock may be more important than precise market timing.
In other recent news, Charles River Laboratories reported its third-quarter 2025 earnings, surpassing analyst expectations. The company achieved an earnings per share (EPS) of $2.43, exceeding the forecasted $2.34. Additionally, revenue reached $1 billion, surpassing predictions. Despite these positive earnings results, the company faced concerns over organic revenue decline and operating margin contraction. These concerns contributed to a decline in the company’s stock, although specific stock movements are not discussed here. Analysts continue to monitor these developments closely. In the broader context, such earnings reports are crucial for investors as they provide insights into the company’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.